Get the Stockscreener App
0.7382
1.01%
-0.0075
After Hours:
.74
0.0018
+0.24%
Durect Corp stock is traded at $0.7382, with a volume of 66,111.
It is down -1.01% in the last 24 hours and down -13.05% over the past month.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
See More
Previous Close:
$0.7457
Open:
$0.72
24h Volume:
66,111
Relative Volume:
1.39
Market Cap:
$22.60M
Revenue:
$8.59M
Net Income/Loss:
$-17.07M
P/E Ratio:
-1.2102
EPS:
-0.61
Net Cash Flow:
$-21.90M
1W Performance:
+1.40%
1M Performance:
-13.05%
6M Performance:
-48.38%
1Y Performance:
-15.27%
1-Day Range:
$0.70
$0.7382
1-Week Range:
$0.70
$0.76
52-Week Range:
$0.70
$1.88
Durect Corp Stock (DRRX) Company Profile
Name
Durect Corp
Sector
Phone
(408) 777-1417
Address
10240 BUBB ROAD, CUPERTINO, CA
Compare DRRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.7382 | 22.60M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-12-20 | Initiated | ROTH Capital | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jan-31-20 | Initiated | B. Riley FBR | Buy |
| Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-20-17 | Reiterated | Laidlaw | Buy |
| Oct-20-17 | Downgrade | Stifel | Buy → Hold |
| Jul-12-17 | Upgrade | Stifel | Hold → Buy |
| Feb-28-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
| May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
| May-01-15 | Reiterated | Stifel | Buy |
| Mar-25-13 | Initiated | Stifel | Buy |
| Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
| Aug-17-12 | Initiated | C.K. Cooper | Buy |
| Jun-23-09 | Initiated | Caris & Company | Buy |
| Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Exclusive Healthcare Conference Alert: DURECT CEO Reveals Latest Developments - Stock Titan
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
Durect Corp Stock (DRRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):